Literature DB >> 10175974

Reassessing quality-of-life instruments in the evaluation of new drugs.

G H Guyatt1, R J Jaeschke.   

Abstract

Investigators use 2 fundamental approaches to the measurement of health-related quality of life (HR-QOL). Generic instruments include health profiles that tap into the full range of HR-QOL issues and are widely applicable, but may lack responsiveness to small but important changes in HR-QOL. Utility measures summarise HR-QOL in a single number between 0 (death) and 1 (full health) and are useful for economic analysis, but may lack responsiveness. Accumulating data suggest the alternatives to generic measures, instruments that are specific to a function or a health problem, are more responsive than generic measures. While direct comparison of the validity and responsiveness of alternative approaches remains limited and should be extended, it is already clear that comprehensive assessment of HR-QOL requires more than 1 type of instrument. To be useful, HR-QOL instruments must be interpretable. Investigators are beginning to elucidate what constitutes trivial, small but important, or large changes in HR-QOL. Approaches include both within- and between-patient global ratings, observing HR-QOL scores in different patient populations, and observing the magnitude of change in HR-QOL with established interventions.

Entities:  

Mesh:

Year:  1997        PMID: 10175974     DOI: 10.2165/00019053-199712060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  25 in total

1.  Measuring health status: what are the necessary measurement properties?

Authors:  G H Guyatt; B Kirshner; R Jaeschke
Journal:  J Clin Epidemiol       Date:  1992-12       Impact factor: 6.437

Review 2.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

3.  The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group.

Authors:  A Laupacis; C Wong; D Churchill
Journal:  Control Clin Trials       Date:  1991-08

4.  Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires.

Authors:  P Tugwell; C Bombardier; W W Buchanan; C Goldsmith; E Grace; K J Bennett; H J Williams; M Egger; G S Alarcon; M Guttadauria
Journal:  Arch Intern Med       Date:  1990-01

5.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

6.  The Duke-UNC Health Profile: an adult health status instrument for primary care.

Authors:  G R Parkerson; S H Gehlbach; E H Wagner; S A James; N E Clapp; L H Muhlbaier
Journal:  Med Care       Date:  1981-08       Impact factor: 2.983

7.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

8.  Life quality of patients with chronic obstructive pulmonary disease.

Authors:  A J McSweeny; I Grant; R K Heaton; K M Adams; R M Timms
Journal:  Arch Intern Med       Date:  1982-03

9.  Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease.

Authors:  C R McGavin; M Artvinli; H Naoe; G J McHardy
Journal:  Br Med J       Date:  1978-07-22

10.  Analysis of quality of life data from a randomized, placebo-controlled heart-failure trial.

Authors:  P K Tandon; H Stander; R P Schwarz
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

View more
  10 in total

Review 1.  Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

Authors:  G Samsa; D Edelman; M L Rothman; G R Williams; J Lipscomb; D Matchar
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

2.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

3.  Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach.

Authors:  Henrica C W de Vet; Raymond W J G Ostelo; Caroline B Terwee; Nicole van der Roer; Dirk L Knol; Heleen Beckerman; Maarten Boers; Lex M Bouter
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 4.147

Review 4.  An overview of children's oral health-related quality of life assessment: from scale development to measuring outcomes.

Authors:  M W Genderson; L Sischo; K Markowitz; D Fine; H L Broder
Journal:  Caries Res       Date:  2013-10-07       Impact factor: 4.056

5.  Quality of Life in Palliative Care.

Authors:  Mellar P Davis; David Hui
Journal:  Expert Rev Qual Life Cancer Care       Date:  2017-11-08

6.  Comparison of the SF6D, the EQ5D, and the oswestry disability index in patients with chronic low back pain and degenerative disc disease.

Authors:  Lars G Johnsen; Christian Hellum; Oystein P Nygaard; Kjersti Storheim; Jens I Brox; Ivar Rossvoll; Gunnar Leivseth; Margreth Grotle
Journal:  BMC Musculoskelet Disord       Date:  2013-04-26       Impact factor: 2.362

7.  Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.

Authors:  Richard Shikiar; Gale Harding; Michael Leahy; Richard D Lennox
Journal:  Health Qual Life Outcomes       Date:  2005-05-20       Impact factor: 3.186

Review 8.  Critical appraisal of the clinical utility of sublingual immunotherapy in allergy.

Authors:  S Aissa; R Ben Jazia; J Ayachi; C Ben Salem; A Hayouni; A Abdelghani; H Ben Saad; M Boussarsar
Journal:  Contemp Clin Trials Commun       Date:  2016-06-18

9.  Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care.

Authors:  Marco H Blanker; Harma Johanna Alma; Tahira Sakina Devji; Marjan Roelofs; Martijn G Steffens; Henk van der Worp
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

10.  Assessment of quality of life in a cohort of newly diagnosed patients on HAART regimen, in resource restricted tribal region of chhattisgarh, India: a prospective study.

Authors:  Harminder Singh; Kamalpreet Kaur; Navin Dulhani; Akash Bansal; Bithika N Kumar; Vinod Kumar Singh Chouhan
Journal:  J Glob Infect Dis       Date:  2013-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.